KiriGenX is positioned to create enterprise value by converting a previously massive undertreated progressive rotator cuff disease segment into a newly treatable surgical opportunity—supported by clinical validation, regulatory execution, layered IP, capital-efficient execution and a value-based ASC adoption strategy.